JERUSALEM--(BUSINESS WIRE)--Feb. 10, 2015--
In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (“Teva”)
announced today that it has filed its 2014 Annual Report on Form 20-F
with the U.S. Securities and Exchange Commission. The Annual Report can
be found on the company’s website at www.tevapharm.com
as well as on the SEC website at www.sec.gov.
In addition, security holders may request a hard copy of the Annual
Report, which includes the company’s complete audited financial
statements, free of charge. Requests can be made by contacting Teva
Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by
phone at (215) 591-8912.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every day.
Headquartered in Israel, Teva is the world’s largest generic medicines
producer, leveraging its portfolio of more than 1,000 molecules to
produce a wide range of generic products in nearly every therapeutic
area. In specialty medicines, Teva has a world-leading position in
innovative treatments for disorders of the central nervous system,
including pain, as well as a strong portfolio of respiratory products.
Teva integrates its generics and specialty capabilities in its global
research and development division to create new ways of addressing unmet
patient needs by combining drug development capabilities with devices,
services and technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visit www.tevapharm.com.
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin
C. Mannix, (215) 591-8912
or
United States
Ran Meir,
(215) 591-3033
or
Israel
Tomer Amitai, 972 (3)
926-7656
or
PR:
Israel
Iris Beck Codner, 972
(3) 926-7687
or
United States
Denise Bradley,
(215) 591-8974